Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

Nature Medicine

Volumn 22, Issue 4, 2016, Pages 362-368

  Hessell, Ann J ^a,b   Jaworski, J Pablo ^a   Epson, Erin ^a   Matsuda, Kenta ^c   Pandey, Shilpi ^a   Kahl, Christoph ^a   Reed, Jason ^b   Sutton, William F ^a   Hammond, Katherine B ^b   Cheever, Tracy A ^a   Barnette, Philip T ^a   Legasse, Alfred W ^a   Planer, Shannon ^a   Stanton, Jeffrey J ^a   Pegu, Amarendra ^c   Chen, Xuejun ^c   Wang, Keyun ^c   Siess, Don ^a   Burke, David ^a   Park, Byung S ^a   Axthelm, Michael K ^a,b   Lewis, Anne ^a   Hirsch, Vanessa M ^c   Graham, Barney S ^c   Mascola, John R ^c   Sacha, Jonah B ^a,b   Haigwood, Nancy L ^a,b   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HUMAN NEUTRALIZING MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUTOPSY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; IMMUNOTHERAPY; INFANT; MALE; NONHUMAN; PRIORITY JOURNAL; SHORT COURSE THERAPY; T CELL DEPLETION; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MACACA; MOTHER CHILD RELATION; PATHOGENICITY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSMISSION; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MACACA; MOTHER-CHILD RELATIONS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84961392349     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4063     Document Type: Article

References (59)

1. Mofenson, L.M. Prevention of mother-To-child HIV-1 transmission-why we still need a preventive HIV immunization strategy. J. Acquir. Immune Defic. Syndr. 58, 359-362 (2011
2. Safrit, J.T., et al. Immunoprophylaxis to prevent mother-To-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 35, 169-177 (2004
3. Voronin, Y., et al. HIV monoclonal antibodies: a new opportunity to further reduce mother-To-child HIV transmission. PLoS Med. 11, e1001616 (2014
4. Mofenson, L.M., & Watts, D.H. Safety of pediatric HIV elimination: the growing population of HIV-And antiretroviral-exposed, but uninfected, infants. PLoS Med. 11, e1001636 (2014
5. Kumwenda, N.I., et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N. Engl. J. Med. 359, 119-129 (2008
6. Persaud, D., et al. Slower clearance of nevirapine-resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-To-child HIV transmission. AIDS Res. Hum. Retroviruses 27, 823-829 (2011
7. Carias, A.M., et al. Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J. Virol. 87, 11388-11400 (2013
8. Demberg, T., & Robert-Guroff, M. Mucosal immunity and protection against HIV-SIV infection: strategies and challenges for vaccine design. Int. Rev. Immunol. 28, 20-48 (2009
9. Haase, A.T. Early events in sexual transmission of HIV and SIV, and opportunities for interventions. Annu. Rev. Med. 62, 127-139 (2011
10. Milush, J.M., et al. Rapid dissemination of SIV following oral inoculation. AIDS 18, 2371-2380 (2004
11. Abel, K., et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J. Virol. 80, 6357-6367 (2006
12. Devito, C., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 165, 5170-5176 (2000
13. Mascola, J.R., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1-SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210 (2000
14. Baba, T.W., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206 (2000
15. Hessell, A.J., et al. Effective, low-Titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951-954 (2009
16. Hessell, A.J., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5, e1000433 (2009
17. Shingai, M., et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061-2074 (2014
18. Pegu, A., et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6, 243ra88 (2014
19. Frankel, S.S., et al. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J. Virol. 72, 9788-9794 (1998
20. Veazey, R.S., et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346 (2003
21. Bomsel, M., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34, 269-280 (2011
22. Parren, P.W., & Burton, D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77, 195-262 (2001
23. Shingai, M., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viremia. Nature 503, 277-280 (2013
24. Ferrantelli, F., et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17, 301-309 (2003
25. Barouch, D.H., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013
26. Caskey, M., et al Viremia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015
27. Bolton, D.L., et al. Human immunodeficiency virus type 1 monoclonal antibodies suppress acute simian-human immunodeficiency virus viremia and limit seeding of cell-Associated viral reservoirs. J. Virol. 90, 1321-1332 (2016
28. Haigwood, N.L., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J. Virol. 78, 5983-5995 (2004
29. Ng, C.T., et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16, 1117-1119 (2010
30. Jaworski, J.P., et al. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J. Virol. 87, 10447-10459 (2013
31. Kong, R., et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 89, 2659-2671 (2015
32. Rudicell, R.S., et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669-12682 (2014
33. Walker, L.M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011
34. Julien, J.P., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 9, e1003342 (2013
35. Moldt, B., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109, 18921-18925 (2012
36. Jayaraman, P., et al. Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3. J. Virol. 81, 822-834 (2007
37. Hansen, S.G., et al. Profound early control of highly pathogenic SIV by an effector memory T cell vaccine. Nature 473, 523-527 (2011
38. Okwundu, C.I., Uthman, O.A., & Okoromah, C.A. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst. Rev. 7, CD007189 (2012
39. Migueles, S.A., & Connors, M. Small molecules and big killers: the challenge of eliminating the latent HIV reservoir. Immunity 36, 320-321 (2012
40. Allers, K., et al. Evidence for the cure of HIV infection by CCR5?32/?32 stem cell transplantation. Blood 117, 2791-2799 (2011
41. Hansen, S.G., et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013
42. Whitney, J.B., et al. Rapid seeding of the viral reservoir prior to SIV viremia in rhesus monkeys. Nature 512, 74-77 (2014
43. Shah, S.K., et al. Research on very early ART in neonates at risk of HIV infection. Lancet Infect. Dis. 14, 797 (2014
44. Persaud, D., et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828-1835 (2013
45. Miller, C.J., et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79, 9217-9227 (2005
46. Hessell, A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007
47. Ledgerwood, J.E., et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289-301 (2015
48. Lynch, R.M., et al. The development of CD4-binding site antibodies during HIV-1 infection. J. Virol. 86, 7588-7595 (2012
49. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals 8th edn. (The National Academies Press, Washington, D.C., 2011
50. Leary, S., et al AVMA Guidelines for the Euthanasia of Animals: 2013 Edition (American Veterinary Medical Association, Schaumburg, Illinois, USA, 2013
51. Wu, X., et al Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010
52. Harouse, J.M., et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian-human immunodeficiency virus SHIVSF162P3. J. Virol. 75, 1990-1995 (2001
53. Cline, A.N., Bess, J.W., Piatak, M. Jr., & Lifson, J.D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations and application to reverse-engineering of vaccines for AIDS. J. Med. Primatol. 34, 303-312 (2005
54. Malouli, D., et al. Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. J. Clin. Invest. 124, 1928-1944 (2014
55. Kozlowski, P.A., Cu-Uvin, S., Neutra, M.R., & Flanigan, T.P. Mucosal vaccination strategies for women. J. Infect. Dis. 179 (suppl. 3), S493-S498 (1999
56. Malherbe, D.C., et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 85, 5262-5274 (2011
57. Hirsch, V.M., et al. Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J. Virol. 69, 955-967 (1995
58. Zhou, T., et al. Transplanting supersites of HIV-1 vulnerability. PLoS One 9, e99881 (2014
59. Malherbe, D.C., et al. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. J. Virol. 88, 12949-12967 (2014